James E. Liebmann

516 total citations
8 papers, 436 citations indexed

About

James E. Liebmann is a scholar working on Oncology, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, James E. Liebmann has authored 8 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Cellular and Molecular Neuroscience and 1 paper in Surgery. Recurrent topics in James E. Liebmann's work include Cancer Treatment and Pharmacology (2 papers), Hormonal and reproductive studies (1 paper) and Hypothalamic control of reproductive hormones (1 paper). James E. Liebmann is often cited by papers focused on Cancer Treatment and Pharmacology (2 papers), Hormonal and reproductive studies (1 paper) and Hypothalamic control of reproductive hormones (1 paper). James E. Liebmann collaborates with scholars based in United States, Switzerland and Japan. James E. Liebmann's co-authors include Michael A. Moskowitz, Arthur J. Schlosberg, John F. Reinhard, Stephen M. Hahn, Dwight Kaufman, Thomas J. McMurry, James B. Mitchell, William DeGraff, C. Murali Krishna and Angelo Russo and has published in prestigious journals such as Science, Cancer and Brain Research.

In The Last Decade

James E. Liebmann

8 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James E. Liebmann United States 8 137 119 100 73 47 8 436
Y.Ziya Ziylan Türkiye 15 141 1.0× 128 1.1× 86 0.9× 96 1.3× 18 0.4× 27 562
Jonathon S. Dunn United States 9 148 1.1× 107 0.9× 48 0.5× 130 1.8× 24 0.5× 10 590
R Gadamski Poland 14 170 1.2× 201 1.7× 53 0.5× 88 1.2× 22 0.5× 56 580
Jean‐François Cloix France 16 375 2.7× 197 1.7× 45 0.5× 85 1.2× 46 1.0× 48 716
Agnese Codignola Italy 11 373 2.7× 165 1.4× 48 0.5× 38 0.5× 22 0.5× 17 521
D. F. J. MASON United Kingdom 12 163 1.2× 175 1.5× 57 0.6× 91 1.2× 36 0.8× 20 548
Amalia Merelli Argentina 15 201 1.5× 78 0.7× 78 0.8× 88 1.2× 36 0.8× 19 579
Kaushik Shah United States 12 253 1.8× 125 1.1× 84 0.8× 170 2.3× 27 0.6× 12 572
Takaharu Ono Japan 11 181 1.3× 96 0.8× 28 0.3× 145 2.0× 44 0.9× 35 511
O. Steinwall Sweden 12 140 1.0× 118 1.0× 52 0.5× 81 1.1× 30 0.6× 27 535

Countries citing papers authored by James E. Liebmann

Since Specialization
Citations

This map shows the geographic impact of James E. Liebmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Liebmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Liebmann more than expected).

Fields of papers citing papers by James E. Liebmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Liebmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Liebmann. The network helps show where James E. Liebmann may publish in the future.

Co-authorship network of co-authors of James E. Liebmann

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Liebmann. A scholar is included among the top collaborators of James E. Liebmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Liebmann. James E. Liebmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Liebmann, James E., Manuel Modiano, Gary I. Cohen, et al.. (2011). Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma. Cancer. 117(22). 5067–5073. 16 indexed citations
2.
Patt, Yehuda Z., James E. Liebmann, Sabine Eckhardt, et al.. (2007). Capecitabine Plus 3-Weekly Irinotecan (XELIRI Regimen) as First-Line Chemotherapy for Metastatic Colorectal Cancer. American Journal of Clinical Oncology. 30(4). 350–357. 36 indexed citations
3.
Temeck, Barbara K., James E. Liebmann, Seth M. Steinberg, et al.. (1996). Phase II trial of 5-fluorouracil, leucovorin, interferon-α-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer. 77(12). 2432–2439. 10 indexed citations
4.
Hahn, Stephen M., James E. Liebmann, John A. Cook, et al.. (1993). Taxol in combination with doxorubicin or etoposide possible antagonism in vitro. Cancer. 72(9). 2705–2711. 57 indexed citations
5.
Krishna, C. Murali, James E. Liebmann, Dwight Kaufman, et al.. (1992). The catecholic metal sequestering agent 1,2-dihydroxybenzene-3, 5-disulfonate confers protection against oxidative cell damage. Archives of Biochemistry and Biophysics. 294(1). 98–106. 99 indexed citations
7.
Reinhard, John F., James E. Liebmann, Arthur J. Schlosberg, & Michael A. Moskowitz. (1979). Serotonin Neurons Project to Small Blood Vessels in the Brain. Science. 206(4414). 85–87. 163 indexed citations
8.
Moskowitz, Michael A., James E. Liebmann, John F. Reinhard, & Arthur J. Schlosberg. (1979). Raphe origin of serotonin-containing neurons within choroid plexus of the rat. Brain Research. 169(3). 590–594. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026